PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Adrenaline/epinephrine - Anaphylaxis
PAD Profile : Adrenaline/epinephrine - Anaphylaxis
Keywords :
adrenaline auto-injectors, adrenaline auto injectors, allergic emergencies, anaphylactic shock, AAIs
Brand Names Include :
Epinephrine, Anapen, EpiPen, Jext, Emerade
Traffic Light Status
Status 1 of 2.
Status :
Green
Important
Formulations :
- Auto-injector
Important Information :
Epipen,/Jext / Emerade - Prescribe by brand.
Injection technique is device-specific
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Guidelines (Local)
01 September 2027
Guidelines (Local)
01 December 2024
Miscellaneous
01 December 2024
Committee Recommendations
Date
Committee Name
Narrative
01 December 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands APC have agreed a variety of resources to support the safe and effective prescribing of adrenaline auto-injectors:
- an Aide Memoire for Primary Care when prescribing adrenaline auto-injectors
- guidance for the prescribing of appropriate quantities
- a checklist / proforma for completion by secondary care when discharging adults or children following anaphylaxis
- an AccuRx template
See below for these documents
The prescribing of Jext, EpiPen and Emerade are supported and should be prescribed by BRAND to ensure the patient receives the correct device.
Patients should receive regular device training. Patient support materials are also available below.
Associated BNF Codes
03. Respiratory System
03.04.03. Allergic emergencies